STATEN BIOTECHNOLOGY
Staten Biotechnology aims to develop novel and innovative strategies for the treatment of dyslipidemia.
STATEN BIOTECHNOLOGY
Industry:
Biotechnology Therapeutics
Founded:
2000-01-01
Address:
Nijmegen, Gelderland, The Netherlands
Country:
The Netherlands
Website Url:
http://www.statenbiotech.com
Total Employee:
1+
Status:
Active
Technology used in webpage:
Google Google Cloud ASP.NET IIS Sectigo SSL ASP.NET 4.0 IIS 8 Sectigo Organization SSL
Similar Organizations
Actigen Ltd
Actigen Ltd is an biotechnology company engaged in the development of human antibody therapeutics.
Raven Biotechnologies
Raven biotechnologies is focused on the development of monoclonal antibody therapeutics for the treatment of cancer.
Xori Corporation
XORI Corporation develops technology for discovery and development of monoclonal antibodies which are used to treat cancers, immune
Investors List
BioGeneration Ventures
BioGeneration Ventures investment in Venture Round - Staten Biotechnology
Official Site Inspections
http://www.statenbiotech.com
- Host name: 5.150.204.35.bc.googleusercontent.com
- IP address: 35.204.150.5
- Location:
- Latitude: 47
- Longitude: 8
- Timezone: Europe/Vaduz
More informations about "Staten Biotechnology"
Staten Biotechnology - Crunchbase Company Profile & Funding
Staten Biotechnology is a developer of a human monoclonal antibody intended to treat dyslipidemia.See details»
Staten Biotechnology - PitchBook
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most. Information on acquisition, funding, cap tables, …See details»
Staten Biotechnology BV - Drug pipelines, Patents, Clinical trials ...
Explore Staten Biotechnology BV with its drug pipeline, therapeutic area, technology platform, 1 clinical trial, 1 news, Disease Domain:Endocrinology and Metabolic Disease, Technology …See details»
Staten Biotechnology (including Vascumab LLC) - VentureRadar
Website: http://www.statenbiotech.com. Develops novel therapies addressing cardiovascular disease and preventing events, focusing on innovative strategies for ...See details»
Staten Biotechnology - Overview, News & Similar companies
Staten Biotechnology contact info: Phone number: +31 357606500 Website: www.statenbiotech.com What does Staten Biotechnology do? Staten Biotechnology B.V. aims …See details»
Staten Biotechnology - Craft
Staten Biotechnology is a company that develops therapies for the prevention of cardiovascular events. It focuses on dyslipidemia management. The company offers STT-5058, an anti …See details»
Staten Biotechnology | Forbion
Www.statenbiotech.com Transistorweg 5J 6534 AT Nijmegen Worked on by. Sander van Deventer, MD PhD Operating Partner. Sander van Deventer has had a critical role in the …See details»
Staten Biotechnology - Products, Competitors, Financials, …
Staten Biotechnology develops technology and strategies for the prevention of cardiovascular events. Use the CB Insights Platform to explore Staten Biotechnology's full profile.See details»
Staten Biotechnology - BioGeneration Ventures
Edward currently serves on the supervisory boards of Azafaros, Escalier BioSciences, Genase Therapeutics, Scenic Biotech, Staten Biotechnology, Synaffix and TigaTx.See details»
Staten Biotechnology B.V. - life-sciences-europe.com
Upcoming Events. J.P. Morgan 42nd Annual Healthcare Conference 2024 San Francisco; BIO 2024 San Diego (BIO International Convention) ISMAR 2023 BrisbaneSee details»
Staten Biotechnology B.V. - BioCentury Company Profiles - BCIQ
Feb 2, 2022 Staten Biotechnology B.V. - BioCentury Company Profiles for the biopharma industrySee details»
STATEN BIOTECHNOLOGY B V innovation strategy - GoodIP
STATEN BIOTECHNOLOGY B V has a total of 31 patent applications. It increased the IP activity by 133.0%. Its first patent ever was published in 2017. It filed its patents most often in United …See details»
Staten Biotechnology CEO, Founder, Key Executive Team, Board of ...
Explore {Staten Biotechnology's key management people. Discover current leadership team members including founders, CEO, other executives and board directors.See details»
Staten Biotechnology in $430m deal with Novo Nordisk
Dec 18, 2018 Under the agreement, Dutch Staten Biotechnology B.V. and Novo Nordisk A/S will collaborate to co-develop Staten’s preclinical dyslipidemia candidate STT-5058 (ARGX-116). …See details»
Novo bags €430M Staten buyout option to boost cardiovascular …
Dec 17, 2018 Novo Nordisk has landed an option to buy Staten Biotechnology in a €430 million ($485 million) deal. The agreement gives Novo the chance to add an anti-apoC3 antibody …See details»
Staten Biotechnology, in collaboration with Novo Nordisk, starts …
Jul 21, 2020 Clinical trajectory initiated towards development of novel treatment for dyslipidaemia NIJMEGEN, The Netherlands–(BUSINESS WIRE)–Staten Biotechnology B.V. …See details»
Staten Biotechnology, in collaboration with Novo ... - Business Wire
Jul 21, 2020 For further information, please contact: Staten Biotechnology B.V Hilde Steineger, CEO T: +31 35 760 65 00 E: [email protected] Instinctif Partners (media enquiries) …See details»
Staten Biotechnology B.V. and Novo Nordisk A/S announce
Dec 17, 2018 Media: Katrine Sperling +45 3079 3883 : [email protected]: Ken Inchausti (US) +1 609 240 9429 : [email protected] Staten Biotechnology:See details»
Staten Biotechnology, in collaboration with Novo Nordisk, starts …
Jul 21, 2020 Staten Biotechnology, in collaboration with Novo Nordisk, starts dosing of anti-apoC3 antibody SST-5058 in First-in-Human TrialSee details»
Staten Biotechnology, in collaboration with Novo Nordisk, starts …
Staten Biotechnology B.V. announced the initiation of dosing of the Company’s lead asset, STT-5058, in a First-in-Human clinical study. STT-5058 is a monoclonal antibody that targets the …See details»